Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2Bone Metabolism and DiseasesMedicinal Plant Pharmacodynamics ResearchBone health and osteoporosis research

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; none of the 38 sources its claims cite is checked for support yet.

Anti-Osteoporotic Potential of Water Extract of Anethum graveolens L. Seeds

Open access

Abstract

Anethum graveolens L., known as European dill, is a versatile herb widely used in both traditional medicine and culinary practices. Despite its long-standing history, the potential impact of the water extract of A. graveolens seeds (WEAG) on bone health remains unexplored. In this study, we investigated the influence of WEAG on osteoclast differentiation and assessed its potential as an anti-osteoporotic agent. WEAG hindered osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand (RANKL) expression in osteoclast-supporting cells and by directly targeting osteoclast precursor cells. WEAG significantly reduced the expression of key osteoclastogenic transcription factors, namely c-Fos and NFATc1, typically induced by RANKL in osteoclast precursors. This reduction was attributed to the suppression of both MAPKs and NF-κB pathways in response to RANKL. In vivo experiments further revealed that WEAG administration effectively reduces trabecular bone loss and weight gain triggered by ovariectomy, mimicking postmenopausal osteoporosis. Furthermore, our comprehensive phytochemical analysis of WEAG identified a range of phytochemical constituents, associated with bone health and weight regulation. Notably, we discovered a specific compound, isorhamnetin-3-O-glucuronide, within WEAG that exhibits anti-osteoclastogenic potential. Overall, this research elucidated the beneficial effects and mechanistic basis of WEAG on osteoclast differentiation and bone loss, indicating its potential as a viable alternative to address bone loss in conditions like postmenopause.

Overview

CoChat Summary

Written by AI from the paper’s full text.

TL;DR

Water extract of *Anethum graveolens* L. seeds (WEAG) inhibits RANKL-induced osteoclast differentiation in vitro and reduces ovariectomy-induced trabecular bone loss and body-weight gain in mice. Phytochemical profiling identified isorhamnetin-3-O-glucuronide as an anti-osteoclastogenic constituent.

Key findings

  • WEAG dose-dependently inhibited osteoclast formation in MLO-Y4/BMM co-cultures and in RANKL-treated BMMs without cytotoxicity; it suppressed VitD3-stimulated RANKL mRNA in MLO-Y4 cells but did not affect OPG mRNA.
  • WEAG reduced RANKL-induced c-Fos and NFATc1 mRNA/protein and osteoclast-specific genes *Atp6v0d2*, *DC-STAMP*, and *Ctsk*; it inhibited JNK and p38 phosphorylation and IκBα degradation, with no effect on ERK phosphorylation.
  • In OVX mice, WEAG at 30 mg/kg/day (WEAG-L) and 100 mg/kg/day (WEAG-H) increased BMD, BV/TV, Tb.N, and Tb.Th and decreased Tb.Sp versus OVX; it also restored OVX-induced body-weight gain but did not reverse uterine atrophy.
  • UHPLC-MS/MS identified six phenolics and five flavonoids in WEAG; isorhamnetin-3-O-glucuronide potently suppressed RANKL-induced osteoclast differentiation without cytotoxicity.

Methods

  • In vitro: BMMs and MLO-Y4 osteocyte-like cells were cultured with WEAG, VitD3, RANKL, and/or M-CSF; osteoclast differentiation was assessed by TRAP activity/staining, Western blot, and quantitative real-time PCR.
  • In vivo: 6-week-old female C57BL/6J mice underwent bilateral OVX; groups (n = 6 each) were sham, OVX, OVX + WEAG 30 mg/kg/day, and OVX + WEAG 100 mg/kg/day, with daily oral gavage for 5 weeks; distal femoral trabecular bone was analyzed by μ-CT.
  • Phytochemical profiling used UHPLC-MS/MS; statistical analysis used one-way ANOVA with Dunnett’s post hoc test or two-way ANOVA with Sidak’s post hoc test.

Limitations

  • The paper states that further investigation is warranted, including an in-depth exploration of WEAG’s influence on osteoclasts and osteoblasts in vivo, to fully uncover the mechanisms behind its beneficial effects in OVX mice.
  • Evident from the text: the in vivo study does not directly establish cellular mechanisms for bone protection, and the OVX model is limited to female mice with two WEAG doses and n = 6 per group.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu15194302

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 WEAG inhibits osteoclast differentiation. (A) BMMs and MLO-Y4 cells were co-cultured with or without WEAG (11.1, 33.3 and 100 µg/mL) in the presence of VitD3 (10 nM) or VitD3 (10 nM) plus RANKL (50 ng/mL) for 5 days. TRAP-stained images (upper panel; scale bar, 200 µm) and the number of TRAP-positive multinucleated cells (MNCs; lower panel) containing more than three nuclei (n = 3/group, except for 0, n = 9). (B) BMMs were treated with or without WEAG (11.1, 33.3 and 100 µg/mL) in the presence of M-CSF (60 ng/mL) and RANKL (50 ng/mL) for 4 days. TRAP-stained images (left panel; scale bar, 200 µm), the cellular TRAP activity (middle panel), and the number of TRAP-positive MNCs (right panel); n = 3/group, except for 0, n = 9. (C) The cell viability of BMMs was assessed using a CCK-8 assay after 24 h of treatment with or without WEAG (11.1, 33.3, and 100 µg/mL) in the presence of M-CSF (60 ng/mL); n = 3/group, except for 0, n = 9. (D) MLO-Y4 cells were treated with or without WEAG (100 μg/mL) and VitD3 (10 nM) for 24 h. RANKL and OPG mRNA expression levels were quantified via real-time PCR (n = 3/group). * p < 0.05, ** p < 0.01 vs. control.
Figure 1 WEAG inhibits osteoclast differentiation. (A) BMMs and MLO-Y4 cells were co-cultured with or without WEAG (11.1, 33.3 and 100 µg/mL) in the presence of VitD3 (10 nM) or VitD3 (10 nM) plus RANKL (50 ng/mL) for 5 days. TRAP-stained images (upper panel; scale bar, 200 µm) and the number of TRAP-positive multinucleated cells (MNCs; lower panel) containing more than three nuclei (n = 3/group, except for 0, n = 9). (B) BMMs were treated with or without WEAG (11.1, 33.3 and 100 µg/mL) in the presence of M-CSF (60 ng/mL) and RANKL (50 ng/mL) for 4 days. TRAP-stained images (left panel; scale bar, 200 µm), the cellular TRAP activity (middle panel), and the number of TRAP-positive MNCs (right panel); n = 3/group, except for 0, n = 9. (C) The cell viability of BMMs was assessed using a CCK-8 assay after 24 h of treatment with or without WEAG (11.1, 33.3, and 100 µg/mL) in the presence of M-CSF (60 ng/mL); n = 3/group, except for 0, n = 9. (D) MLO-Y4 cells were treated with or without WEAG (100 μg/mL) and VitD3 (10 nM) for 24 h. RANKL and OPG mRNA expression levels were quantified via real-time PCR (n = 3/group). * p < 0.05, ** p < 0.01 vs. control.CC BY · PubMed Central
Figure 2 WEAG inhibits RANKL-induced signaling pathways in BMMs. (A,B) BMMs were treated with or without WEAG (100 µg/mL) and RANKL (50 ng/mL) for the indicated durations. Protein expression levels of the indicated proteins (A) and mRNA expression levels of the indicated genes (B) were assessed using Western blotting and real-time PCR (n = 3/group), respectively. (C) BMMs were stimulated with RANKL for the indicated time intervals following a 3 h pretreatment with WEAG. Protein levels of phosphorylated and non-phosphorylated forms were detected via Western blotting. ** p < 0.01 vs. control.
Figure 2 WEAG inhibits RANKL-induced signaling pathways in BMMs. (A,B) BMMs were treated with or without WEAG (100 µg/mL) and RANKL (50 ng/mL) for the indicated durations. Protein expression levels of the indicated proteins (A) and mRNA expression levels of the indicated genes (B) were assessed using Western blotting and real-time PCR (n = 3/group), respectively. (C) BMMs were stimulated with RANKL for the indicated time intervals following a 3 h pretreatment with WEAG. Protein levels of phosphorylated and non-phosphorylated forms were detected via Western blotting. ** p < 0.01 vs. control.CC BY · PubMed Central
Figure 3 WEAG mitigates bone loss in OVX mice. (A) Schematic representation of the experimental protocols. (B,C) Sham-operated (sham) or OVX mice were orally administered with either vehicle, WEAG at a dose of 30 mg/kg (WEAG-L), or 100 mg/kg (WEAG-H) for 5 weeks. (B) µ-CT images of the distal femurs and subsequent evaluation of BMD and bone morphometric parameters in the femoral trabecular bone (n = 6/group). (C) Assessment of changes in body weight and uterine weight (n = 6/group). ** p < 0.01 vs. OVX group.
Figure 3 WEAG mitigates bone loss in OVX mice. (A) Schematic representation of the experimental protocols. (B,C) Sham-operated (sham) or OVX mice were orally administered with either vehicle, WEAG at a dose of 30 mg/kg (WEAG-L), or 100 mg/kg (WEAG-H) for 5 weeks. (B) µ-CT images of the distal femurs and subsequent evaluation of BMD and bone morphometric parameters in the femoral trabecular bone (n = 6/group). (C) Assessment of changes in body weight and uterine weight (n = 6/group). ** p < 0.01 vs. OVX group.CC BY · PubMed Central
Figure 4 UHPLC-MS/MS analysis of WEAG. (A) Base peak chromatogram. (B) Extracted ion chromatogram of identified phytochemicals. 1, quinic acid; 2, 3-O-caffeoylquinic acid; 3, 5-O-caffeoylquinic acid; 4, caffeic acid; 5, schaftoside; 6, feruloylquinic acid; 7, quercetin-3-O-rutinoside; 8, quercetin-O-glucuronide; 9, kaempferol-3-O-glucuronide; 10, isorhamnetin-3-O-glucuronide; 11, malonyl-tri-O-caffeoylquinic acid.
Figure 4 UHPLC-MS/MS analysis of WEAG. (A) Base peak chromatogram. (B) Extracted ion chromatogram of identified phytochemicals. 1, quinic acid; 2, 3-O-caffeoylquinic acid; 3, 5-O-caffeoylquinic acid; 4, caffeic acid; 5, schaftoside; 6, feruloylquinic acid; 7, quercetin-3-O-rutinoside; 8, quercetin-O-glucuronide; 9, kaempferol-3-O-glucuronide; 10, isorhamnetin-3-O-glucuronide; 11, malonyl-tri-O-caffeoylquinic acid.CC BY · PubMed Central
Figure 5 Impact of phytochemicals in WEAG on RANKL-induced osteoclast differentiation. (A) Cell viability of BMMs was assessed using a CCK-8 assay after 24 h of treatment with or without the phytochemicals (each 10 and 20 µM) in the presence of M-CSF (60 ng/mL); n = 3/group, except for 0, n = 9. (B) BMMs were treated with or without the phytochemicals (each 10 and 20 µM) in the presence of M-CSF and RANKL for 4 days. The number of TRAP(+) MNCs containing more than three nuclei (upper panel; n = 3/group) and representative images of TRAP staining treated with isorhamnetin-3-O-glucuronide (lower panel; scale bar, 200 µm). 1, quinic acid; 2, 5-O-caffeoylquinic acid; 3, caffeic acid; 4, schaftoside; 5, feruloylquinic acid; 6, quercetin-3-O-rutinoside; 7, quercetin-O-glucuronide; 8, kaempferol-3-O-glucuronide; 9, isorhamnetin-3-O-glucuronide. ** p < 0.01 vs. control.
Figure 5 Impact of phytochemicals in WEAG on RANKL-induced osteoclast differentiation. (A) Cell viability of BMMs was assessed using a CCK-8 assay after 24 h of treatment with or without the phytochemicals (each 10 and 20 µM) in the presence of M-CSF (60 ng/mL); n = 3/group, except for 0, n = 9. (B) BMMs were treated with or without the phytochemicals (each 10 and 20 µM) in the presence of M-CSF and RANKL for 4 days. The number of TRAP(+) MNCs containing more than three nuclei (upper panel; n = 3/group) and representative images of TRAP staining treated with isorhamnetin-3-O-glucuronide (lower panel; scale bar, 200 µm). 1, quinic acid; 2, 5-O-caffeoylquinic acid; 3, caffeic acid; 4, schaftoside; 5, feruloylquinic acid; 6, quercetin-3-O-rutinoside; 7, quercetin-O-glucuronide; 8, kaempferol-3-O-glucuronide; 9, isorhamnetin-3-O-glucuronide. ** p < 0.01 vs. control.CC BY · PubMed Central

Verification

Claims the paper makes

19 Own result · 14 Check pending · 6 Own interpretation · 5 No full text of the sources · 5 Not checked yet

  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Create a free account to see these assumptions.

13 more claims

Create a free account to see all 49 claims and to verify the 25 references still open.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 46 references

Cited by

See all 2

Metadata

Authors
Jang, S.-A., Lee, S.-J., Hwang, Y.-H., & Ha, H.
Affiliations
  • KT&G (South Korea) (KR)
  • Korea Institute of Oriental Medicine (KR)
Corresponding author
Ha, Hyunil
Venue
Nutrients
Publisher
MDPI AG
Published
2023-10-09
Volume
15
Issue
19
Pages
4302
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4387451985
Cited by
2
References
46
Citations by year
2024: 1
FWCI
0.08
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Korea Institute of Oriental Medicine, Ministry of Science and ICT, Republic of Korea (KSN2022332)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Medicinal Plant Pharmacodynamics Research
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
dill, dill seeds, anti-osteoporotic activity, osteoclastogenesis, RANKL, c-fos, NFATc1, MAPK signaling, NF-κB signaling, postmenopausal osteoporosis, ovariectomy-induced bone loss, phytochemicals, bone health, weight gain
MeSH terms
Bone Resorption, Cell Differentiation, Female, Humans, Osteoclasts, Osteogenesis, Ovariectomy, NF-kappa B, Anethum graveolens, NFATC Transcription Factors, RANK Ligand, Phytochemicals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-Osteoporotic Potential of Water Extract of Anethum graveolens L. Seeds. https://app.cochat.ai/papers/10.3390/nu15194302
The paper
Jang, S.-A., Lee, S.-J., Hwang, Y.-H., & Ha, H. (2023). Anti-Osteoporotic Potential of Water Extract of Anethum graveolens L. Seeds. Nutrients. https://doi.org/10.3390/nu15194302